Zai Lab's Niraparib Shows 3X Longer PFS Compared to Placebo In Ovarian Cancer


Zai Lab Limited ZLAB presented data from the Phase 3 PRIME study of Zejula (niraparib) as maintenance therapy in Chinese ovarian cancer patients.

  • Zejula demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a tolerable safety profile with newly diagnosed ovarian cancer following response to platinum-based chemotherapy, regardless of biomarker status.
  • The median Progression-free survival (PFS) was significantly longer for patients treated with niraparib than placebo: 24.8 months versus 8.3 months.
  • Overall survival data are still immature (percentage of death in niraparib and placebo groups are 14.5% vs. 21.7%); there is a trend in favor of niraparib at the data cut-off.
  • The safety profile of niraparib was improved with the individualized starting dosing (ISD) prospectively applied to all patients. 
  • In December 2021, the National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) was updated to include Zejula as a first-line maintenance treatment of ovarian cancer.
  • Price Action: ZLAB shares traded lower by 1.63% at $38.10 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBriefsOvarian CancerPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!